CDNA
Neutral signalScored 2026-08-10 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
CareDx, Inc
- Nom
- CareDx, Inc
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NASDAQ
- Capitalisation
- $3.6B
- Employés
- 763
- PDG
- John Walter Hanna Jr.
- Site web
- https://www.caredx.com
- Marché
- BLLNFLGTMYGNNTRAQGENVCYT
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 267 479 titres (~10 251 571,84 $ US)
- Insiders
- Bickerstaff GeorgeCOURNOYER CHRISTINEGoldberg MichaelHanna John Walter JRValantine Hannah
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$3,803,545
Avg sell (VWAP, 90d window) $46.84 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$774,348 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-05
- Last synced
-
2026-08-11 09:46:50
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-05 | Bickerstaff George | Sell · S | 20,000 | $46.28 | $925,700 | Form 4 |
| 2026-08-05 | Novack Jeffrey Adam | Sell · S · 10b5-1 | 500 | $46.75 | $23,375 | Form 4 |
| 2026-08-04 | COURNOYER CHRISTINE | Sell · S · 10b5-1 | 16,000 | $46.94 | $750,973 | Form 4 |
| 2026-08-04 | Goldberg Michael | Sell · S | 44,700 | $47.06 | $2,103,497 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-03-06 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
| 2021-12-29 | Tom Malinowski | Purchase | $1,001 - $15,000 |
| 2021-03-02 | Tom Malinowski | Purchase | $15,001 - $50,000 |
| 2021-01-11 | Tom Malinowski | Sale (Partial) | $1,001 - $15,000 |
| 2021-01-08 | Tom Malinowski | Sale (Partial) | $1,001 - $15,000 |
| 2021-01-06 | Tom Malinowski | Sale (Partial) | $15,001 - $50,000 |
| 2020-12-23 | Tom Malinowski | Purchase | $1,001 - $15,000 |
| 2020-12-07 | Tom Malinowski | Purchase | $1,001 - $15,000 |
| 2020-11-16 | Tom Malinowski | Purchase | $1,001 - $15,000 |
| 2020-10-09 | Tom Malinowski | Sale (Partial) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-08-10 Drivers: fundamentals. Moteurs : fondamentaux.
CDNA delivered a strong Q2 2026 earnings beat (68% EPS surprise) with 52% revenue growth, generating a legitimate positive catalyst, but the ~$10.25M in insider selling immediately post-earnings materially undermines…
The first sentence of the analysis written for CDNA on 2026-08-10 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 2.86 · operating margin -6.6% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 67.6% | 67.2% | 63.6% | 65.1% | 67.1% | |
| Ebit Margin | -6.6% | -16.1% | -37.4% | -23.7% | -10.8% | |
| Ebitda Margin | -1.2% | -10.2% | -30.3% | -18.7% | -6.8% | |
| Operating Profit Margin | -6.6% | 12.2% | -72.5% | -24.0% | -10.0% | |
| Pretax Profit Margin | -5.6% | 15.8% | -67.8% | -23.7% | -10.8% | |
| Continuous Operations Profit Margin | -5.6% | 15.7% | -67.9% | -23.8% | -10.3% | |
| Net Profit Margin | -5.6% | 15.7% | -67.9% | -23.8% | -10.3% | |
| Bottom Line Profit Margin | -5.6% | 15.7% | -67.9% | -23.8% | -10.3% | |
| Current Ratio | 2.862 | 3.937 | 4.018 | 5.105 | 5.606 | |
| Quick Ratio | 2.565 | 3.719 | 3.769 | 4.852 | 5.384 | |
| Solvency Ratio | -0.009 | 0.642 | -0.829 | -0.541 | -0.186 | |
| Cash Ratio | 0.728 | 1.283 | 1.053 | 1.184 | 4.508 | |
| Price To Earnings Ratio | -47.100 | 21.410 | -3.390 | -7.924 | -77.085 | |
| Price To Earnings Growth Ratio | 0.336 | -0.167 | -0.023 | -0.055 | -1.623 | |
| Forward Price To Earnings Growth Ratio | 0.336 | -0.167 | -0.023 | -0.055 | -1.623 | |
| Price To Earnings Diluted Ratio | -47.100 | 23.022 | -3.390 | -7.924 | -77.085 | |
| Price To Earnings Diluted Growth Ratio | 0.329 | -0.182 | -0.023 | -0.055 | -1.623 | |
| Price To Book Ratio | 3.312 | 2.986 | 2.469 | 1.412 | 5.100 | |
| Price To Sales Ratio | 2.643 | 3.385 | 2.302 | 1.891 | 8.016 | |
| Price To Free Cash Flow Ratio | 27.795 | 35.796 | -23.352 | -12.273 | -60.069 | |
| Price To Operating Cash Flow Ratio | 23.885 | 29.696 | -35.087 | -24.106 | -123.143 | |
| Debt To Assets Ratio | 0.063 | 0.058 | 0.073 | 0.072 | 0.038 | |
| Debt To Equity Ratio | 0.086 | 0.075 | 0.131 | 0.090 | 0.046 | |
| Debt To Capital Ratio | 0.080 | 0.070 | 0.116 | 0.083 | 0.044 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.363 | 1.298 | 1.786 | 1.260 | 1.216 | |
| Working Capital Turnover Ratio | 1.768 | 1.340 | 1.024 | 0.964 | 1.059 | |
| Operating Cash Flow Ratio | 0.468 | 0.426 | -0.236 | -0.332 | -0.250 | |
| Operating Cash Flow Sales Ratio | 0.111 | 0.114 | -0.066 | -0.078 | -0.065 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.859 | 0.830 | 1.503 | 1.964 | 2.050 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 1.605 | 1.341 | -0.537 | -0.647 | -0.904 | |
| Capital Expenditure Coverage Ratio | 7.108 | 5.868 | -1.990 | -1.037 | -0.952 | |
| Dividend Paid And Capex Coverage Ratio | 7.108 | 5.868 | -1.990 | -1.037 | -0.952 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -207.240 | -30.697 | -7.033 | -9.256 | -101.410 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 67.5% | ▲0.4% | ▲1.4% |
| Ebit Margin | -6.6% | ▲9.5% | ▲12.3% |
| Ebitda Margin | -1.2% | ▲9.0% | ▲12.2% |
| Operating Profit Margin | -6.6% | ▼-18.8% | ▲13.6% |
| Pretax Profit Margin | -5.5% | ▼-21.4% | ▲12.9% |
| Continuous Operations Profit Margin | -5.6% | ▼-21.4% | ▲12.8% |
| Net Profit Margin | -5.6% | ▼-21.4% | ▲12.8% |
| Bottom Line Profit Margin | -5.6% | ▼-21.4% | ▲12.8% |
| Current Ratio | 2.862 | ▼-1.075 | ▼-1.444 |
| Quick Ratio | 2.565 | ▼-1.154 | ▼-1.493 |
| Solvency Ratio | -0.009 | ▼-0.651 | ▲0.176 |
| Cash Ratio | 0.728 | ▼-0.555 | ▼-1.023 |
| Price To Earnings Ratio | -47.100 | ▼-68.510 | ▼-24.282 |
| Price To Earnings Growth Ratio | 0.336 | ▲0.503 | ▲0.643 |
| Forward Price To Earnings Growth Ratio | 0.336 | ▲0.503 | ▲0.643 |
| Price To Earnings Diluted Ratio | -47.100 | ▼-70.121 | ▼-24.605 |
| Price To Earnings Diluted Growth Ratio | 0.329 | ▲0.512 | ▲0.640 |
| Price To Book Ratio | 3.312 | ▲0.327 | ▲0.257 |
| Price To Sales Ratio | 2.643 | ▼-0.742 | ▼-1.004 |
| Price To Free Cash Flow Ratio | 27.795 | ▼-8.001 | ▲34.216 |
| Price To Operating Cash Flow Ratio | 23.885 | ▼-5.811 | ▲49.636 |
| Debt To Assets Ratio | 0.063 | ▲0.006 | ▲0.003 |
| Debt To Equity Ratio | 0.086 | ▲0.011 | ▲0.001 |
| Debt To Capital Ratio | 0.080 | ▲0.010 | ▲0.001 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.363 | ▲0.066 | ▼-0.021 |
| Working Capital Turnover Ratio | 1.768 | ▲0.427 | ▲0.537 |
| Operating Cash Flow Ratio | 0.468 | ▲0.042 | ▲0.453 |
| Operating Cash Flow Sales Ratio | 0.111 | ▼-0.003 | ▲0.108 |
| Free Cash Flow Operating Cash Flow Ratio | 0.859 | ▲0.030 | ▼-0.582 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 1.605 | ▲0.263 | ▲1.433 |
| Capital Expenditure Coverage Ratio | 7.108 | ▲1.240 | ▲5.309 |
| Dividend Paid And Capex Coverage Ratio | 7.108 | ▲1.240 | ▲5.309 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -207.240 | ▼-176.543 | ▼-136.113 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.00B | $1.13B | $645.2M | $608.4M | $2.38B | |
| Enterprise value | $964.7M | $1.04B | $597.2M | $557.5M | $2.05B | |
| EV / Sales | 2.54x | 3.13x | 2.13x | 1.73x | 6.91x | |
| EV / Op. cash flow | 22.95x | 27.43x | -32.48x | -22.09x | -106.19x | |
| EV / Free cash flow | 26.71x | 33.06x | -21.62x | -11.25x | -51.80x | |
| EV / EBITDA | -207.24x | -30.70x | -7.03x | -9.26x | -101.41x | |
| Net debt / EBITDA | 8.43x | 2.54x | 0.56x | 0.85x | 16.19x | |
| Current ratio | 2.86x | 3.94x | 4.02x | 5.11x | 5.61x | |
| Income quality | -1.97x | 0.72x | 0.10x | 0.33x | 0.63x | |
| Graham number | — | $13 | — | — | — | |
| Graham net-net | $2 | $4 | $1 | $5 | $6 | |
| Tax burden | 101.3% | 99.4% | 100.1% | 100.5% | 95.6% | |
| Interest burden | 84.1% | -98.3% | 181.5% | 100.0% | 100.0% | |
| Working capital | $167.3M | $262.5M | $235.6M | $311.9M | $356.1M | |
| Invested capital | $295.3M | $398.9M | $386.8M | $462.7M | $483.3M | |
| Return on assets | -5.2% | 10.7% | -40.8% | -14.1% | -5.4% | |
| Operating ROA | -5.5% | 8.5% | -40.3% | -13.9% | -6.4% | |
| Return on tangible assets | -6.3% | 12.7% | -50.0% | -16.6% | -6.4% | |
| Return on equity | -7.0% | 13.9% | -72.8% | -17.8% | -6.6% | |
| Return on invested capital | -7.6% | 9.9% | -51.5% | -16.3% | -5.8% | |
| Return on capital employed | -7.8% | 10.1% | -52.3% | -16.5% | -6.1% | |
| Earnings yield | -2.1% | 4.7% | -29.5% | -12.6% | -1.3% | |
| Free cash flow yield | 3.6% | 2.8% | -4.3% | -8.1% | -1.7% | |
| Capex / Op. cash flow | 14.1% | 17.0% | -50.3% | -96.4% | -105.0% | |
| Capex / Depreciation | 29.0% | 32.8% | 46.6% | 152.0% | 170.5% | |
| Capex / Sales | 1.6% | 1.9% | 3.3% | 7.6% | 6.8% | |
| SG&A / Sales | 55.3% | 61.6% | 71.8% | 61.0% | 51.4% | |
| R&D / Sales | 18.8% | 21.7% | 29.2% | 28.1% | 25.8% | |
| Stock comp / Sales | 9.2% | 19.9% | 17.5% | 14.5% | 12.2% | |
| Intangibles / Total assets | 17.5% | 16.0% | 18.4% | 14.8% | 15.4% | |
| Days sales outstanding | 41d | 71d | 66d | 75d | 74d | |
| Days payables outstanding | 30d | 26d | 46d | 32d | 50d | |
| Operating cycle | 120d | 136d | 136d | 138d | 138d | |
| Cash conversion cycle | 90d | 110d | 90d | 105d | 88d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-07 CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On August 5, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an aggregate of 97,090 shares of common stock. With respect to 34 of the new employees, an aggregate of 93,090 of the RSUs will vest o.
- 2026-07-31 CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company''s newly appointed Executive Advisor, certain stock awards as an inducement material to Mr. McNally''s employment with CareDx. CareDx granted 15,822 shares of common stock restricted stock units (RSUs) to Mr. McNally. The RSU awards were made pursua.
- 2026-07-31 Why CareDx Stock Jumped Today CareDx is helping to improve outcomes for transplant patients. The health monitor''s non-invasive tests are in high demand.
- 2026-07-30 CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
- 2026-07-30 CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates CareDx (CDNA) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.1 per share a year ago.
- 2026-07-30 CareDx Q2 Earnings Call Highlights CareDx NASDAQ: CDNA reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform.
- 2026-07-30 CareDx Announces Second Quarter 2026 Financial Results BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue of $132 million, an increase of 52% year-over-year Testing Services revenue of $100 million, an increase of 61% year-over-year, and Testing Services volume of approximately 58,000, an increase of 17% year-o.
- 2026-07-23 CareDx (CDNA) Earnings Expected to Grow: Should You Buy? CareDx (CDNA) doesn''t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 2026-07-21 Amova Asset Management Americas Inc. Increases Position in CareDx, Inc. $CDNA Amova Asset Management Americas Inc. raised its holdings in shares of CareDx, Inc. (NASDAQ: CDNA) by 2.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,475,126 shares of the company''s stock after purchasing an additional 28,510 shares during the period. Amova Asset
- 2026-07-20 CareDx''s Growth Prospects With Naveris Keep Me Bullish CareDx has a transplant-testing franchise that taps into recurring surveillance demand and has deeper integration into transplant centers. I also think CDNA''s AlloHeme gives them longer-term optionality in post-cell-therapy monitoring. More recently, CDNA sold Lab Products and purchased Naveris. These major strategic M&A deals mean CDNA now has a potential growth engine in oncology.